3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroendocrine Tumors
12
Meningioma
5
Prostatic Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Neuroblastoma
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Merkel Cell
2
Sarcoma, Synovial
1
Recurrence
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Hypertension
1
Gastro-enteropancreatic neuroendocrine tumor
1
Extensive Stage Small Cell Lung Cancer
1
Esthesioneuroblastoma, Olfactory
1
Disease Progression
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Carcinoma
1
Carcinoid Tumor
1
Advanced Lung Neuroendocrine Tumor
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Adenoma, Islet Cell
1
Interventions
Specimen Handling
4
Gemcitabine
4
fludarabine
3
aldesleukin
3
Radiosurgery
3
Oxaliplatin
3
Fluorouracil
3
Endoscopic Mucosal Resection
3
Cyclophosphamide
3
Cetuximab
3
Bevacizumab
3
130-nm albumin-bound paclitaxel
3
Tomography, X-Ray Computed
2
Surveys and Questionnaires
2
Sunitinib
2
Pemetrexed
2
IDRX-42
2
Folfox protocol
2
Endoscopy, Digestive System
2
Biopsy
2
trastuzumab deruxtecan
1
tislelizumab
1
sodium thiosulfate
1
sodium propionate
1
semaglutide
1
s-formylglutathione hydrolase
1
repotrectinib
1
regorafenib
1
plecanatide
1
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
lutetium Lu 177 dotatate
×
90 days
×
Clear all
No trials found.